Form 4: Arcutis Biotherapeutics Director Howard G. Welgus Sells 10,000 Shares Under 10b5-1 Trading Plan

Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics (ARQT) common stock on May 1, 2025, at a weighted average price of $14.6357, under a pre-arranged 10b5-1 trading plan.

Summary

• On May 1, 2025, Howard G. Welgus, a director of Arcutis Biotherapeutics, Inc. (ARQT), sold 10,000 shares of common stock.
• The sale was executed under a 10b5-1 trading plan adopted on March 5, 2024, with a plan end date of May 30, 2025.
• The shares were sold at a weighted average price of $14.6357, with individual transaction prices ranging from $14.19 to $14.95.
• Following the transaction, Welgus directly owns 111,944 shares of Arcutis Biotherapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by a company director under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by company directors are a normal part of corporate governance. It is important to note that the sale was executed under a pre-arranged 10b5-1 trading plan, which allows corporate insiders to sell shares without being accused of trading on non-public information.

Stakeholder Impact

• The sale of shares by a director could have a minor impact on shareholder confidence, but the existence of a 10b5-1 trading plan mitigates concerns about insider trading.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Howard G. Welgus, Form 4, Stock Sale, 10b5-1 Trading Plan, Director, Insider Trading